Loading...
OTCM
NPHC
Market cap4mUSD
Dec 05, Last price  
0.00USD
1D
20.00%
1Q
500.00%
Jan 2017
-92.68%
IPO
-100.00%
Name

Nutra Pharma Corp

Chart & Performance

D1W1MN
OTCM:NPHC chart
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
-32.84%
Revenues
0k
-100.00%
00020,20004,045618,0101,432,056159,599203,290122,198594,505291,302168,356120,979130,596104,39351,89797,7350
Net income
0k
P
-2,738,456-7,986,853-5,152,164-2,431,178-164,951-4,162,108-2,301,641-3,061,464-4,397,198-3,612,351-4,342,964-2,532,985-5,391,981-3,447,613-4,028,748-3,884,695-1,661,322-769,184-3,465,6390
CFO
0k
P
-78,873-1,512,314-1,529,477-1,737,081-805,367-976,094-1,956,102-1,358,173-1,888,111-721,242-531,037-148,129-1,018,188-1,356,498-1,138,347-999,949-743,659-878,086-1,744,4690

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company offers Nyloxin and Nyloxin Extra Strength products, which are used as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps, and neuropathic pain, as well as a topical gel for treating joint pain, and pain associated with arthritis and repetitive stress; Pet Pain-Away, a homeopathic, non–narcotic, non–addictive, and over–the–counter pain reliever to treat chronic pain in companion animals; Luxury Feet, an over-the-counter pain reliever and anti–inflammatory product to treat pain or discomfort due to high heels and stilettos; Nyloxin Military Strength for treating pain to the United States Military and Veteran's Administration; and Equine Pain-Away, an over-the-counter topical pain reliever to relieve pain in horses. It is also involved in developing RPI-78M to treat neurological diseases and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases comprising human immunodeficiency virus/AIDS and herpes, as well as for general anti-viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain. The company was incorporated in 2000 and is based in Plantation, Florida.
IPO date
Oct 09, 2001
Employees
4
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT